Please wait while the formulary information is being retrieved.
RIBAVIRIN (RIBAVIRIN)
- Respiratory syncytial virus infection
- Chronic hepatitis C - genotype 1
- Chronic hepatitis C - genotype 3
- Chronic hepatitis C - genotype 4
- Chronic hepatitis C - genotype 2
- Virazole Solution For Inhalation
- Ribavirin Tablet
- Ribavirin Solution For Inhalation
- Ribavirin Capsule
- Ribasphere Tablet
- Ribasphere Capsule
- By Indication
6 gram solution for inhalation
- Dosage information is not available
200 mg tablet
- 3 tablets (600 mg) by oral route 2 times per day
600 mg tablet
- 1 tablet (600 mg) by oral route 2 times per day with food
6 gram solution for inhalation
- Dosage information is not available
200 mg capsule
- 2 capsules (400 mg) by oral route in the morning and 3 capsules (600 mg) in the evening (patients weighing less than or equal to 75 kg)
600 mg tablet
- 1 tablet (600 mg) by oral route 2 times per day with food
200 mg capsule
- 2 capsules (400 mg) by oral route in the morning and 3 capsules (600 mg) in the evening (patients weighing less than or equal to 75 kg)
Chronic hepatitis C - genotype 1
- 2 capsules (400 mg) by oral route 2 times per day for patients weighing less than or equal to 65 kg
- 2 capsules (400 mg) by oral route 2 times per day for patients weighing less than or equal to 65 kg for 24 weeks
- 2 capsules (400 mg) by oral route 2 times per day for patients weighing less than or equal to 65 kg for 48 weeks
- 2 capsules (400 mg) by oral route in the morning and 3 capsules (600 mg) in the evening for patients weighing 66 kg to 80 kg
- 2 capsules (400 mg) by oral route in the morning and 3 capsules (600 mg) in the evening for patients weighing 66 kg to 80 kg for 24 weeks
- 2 capsules (400 mg) by oral route in the morning and 3 capsules (600 mg) in the evening for patients weighing 66 kg to 80 kg for 48 weeks
- 2 tablets (400 mg) by oral route 2 times per day in the morning and at bedtime
- 2 capsules (400 mg) by oral route in the morning and 3 capsules (600 mg) in the evening for patients weighing less than or equal to 75Kg
- 2 capsules (400 mg) by oral route in the morning and 3 capsules (600 mg) in the evening for patients weighing less than or equal to 75Kg for 24 weeks
- 2 capsules (400 mg) by oral route in the morning and 3 capsules (600 mg) in the evening (patients weighing less than or equal to 75 kg)
- 3 capsules (600 mg) by oral route 2 times per day for patients weighing more than 75 kg for 24 weeks
- 3 capsules (600 mg) by oral route 2 times per day for patients weighing more than 75 kg
- 3 tablets (600 mg) by oral route 2 times per day
- 3 capsules (600 mg) by oral route 2 times per day for patients weighing 81 kg to 105 kg
- 3 capsules (600 mg) by oral route 2 times per day for patients weighing 81 kg to 105 kg for 24 weeks
- 3 capsules (600 mg) by oral route 2 times per day for patients weighing 81 kg to 105 kg for 48 weeks
- 3 capsules (600 mg) by oral route in the morning and 4 capsules (800 mg) in the evening for patients weighing more than 105 kg
- 3 capsules (600 mg) by oral route in the morning and 4 capsules (800 mg) in the evening for patients weighing more than 105 kg for 24 weeks
- 3 capsules (600 mg) by oral route in the morning and 4 capsules (800 mg) in the evening for patients weighing more than 105 kg for 48 weeks
Chronic hepatitis C - genotype 2
- 2 capsules (400 mg) by oral route 2 times per day for patients weighing less than or equal to 65 kg
- 2 capsules (400 mg) by oral route 2 times per day for patients weighing less than or equal to 65 kg for 24 weeks
- 2 capsules (400 mg) by oral route 2 times per day for patients weighing less than or equal to 65 kg for 48 weeks
- 2 capsules (400 mg) by oral route in the morning and 3 capsules (600 mg) in the evening for patients weighing 66 kg to 80 kg
- 2 capsules (400 mg) by oral route in the morning and 3 capsules (600 mg) in the evening for patients weighing 66 kg to 80 kg for 24 weeks
- 2 capsules (400 mg) by oral route in the morning and 3 capsules (600 mg) in the evening for patients weighing 66 kg to 80 kg for 48 weeks
- 2 tablets (400 mg) by oral route 2 times per day in the morning and at bedtime
- 2 capsules (400 mg) by oral route in the morning and 3 capsules (600 mg) in the evening for patients weighing less than or equal to 75Kg
- 2 capsules (400 mg) by oral route in the morning and 3 capsules (600 mg) in the evening for patients weighing less than or equal to 75Kg for 24 weeks
- 2 capsules (400 mg) by oral route in the morning and 3 capsules (600 mg) in the evening (patients weighing less than or equal to 75 kg)
- 3 capsules (600 mg) by oral route 2 times per day for patients weighing more than 75 kg for 24 weeks
- 3 capsules (600 mg) by oral route 2 times per day for patients weighing more than 75 kg
- 3 tablets (600 mg) by oral route 2 times per day
- 3 capsules (600 mg) by oral route 2 times per day for patients weighing 81 kg to 105 kg
- 3 capsules (600 mg) by oral route 2 times per day for patients weighing 81 kg to 105 kg for 24 weeks
- 3 capsules (600 mg) by oral route 2 times per day for patients weighing 81 kg to 105 kg for 48 weeks
- 3 capsules (600 mg) by oral route in the morning and 4 capsules (800 mg) in the evening for patients weighing more than 105 kg
- 3 capsules (600 mg) by oral route in the morning and 4 capsules (800 mg) in the evening for patients weighing more than 105 kg for 24 weeks
- 3 capsules (600 mg) by oral route in the morning and 4 capsules (800 mg) in the evening for patients weighing more than 105 kg for 48 weeks
Chronic hepatitis C - genotype 3
- 2 capsules (400 mg) by oral route 2 times per day for patients weighing less than or equal to 65 kg
- 2 capsules (400 mg) by oral route 2 times per day for patients weighing less than or equal to 65 kg for 24 weeks
- 2 capsules (400 mg) by oral route 2 times per day for patients weighing less than or equal to 65 kg for 48 weeks
- 2 capsules (400 mg) by oral route in the morning and 3 capsules (600 mg) in the evening for patients weighing 66 kg to 80 kg
- 2 capsules (400 mg) by oral route in the morning and 3 capsules (600 mg) in the evening for patients weighing 66 kg to 80 kg for 24 weeks
- 2 capsules (400 mg) by oral route in the morning and 3 capsules (600 mg) in the evening for patients weighing 66 kg to 80 kg for 48 weeks
- 2 tablets (400 mg) by oral route 2 times per day in the morning and at bedtime
- 2 capsules (400 mg) by oral route in the morning and 3 capsules (600 mg) in the evening for patients weighing less than or equal to 75Kg
- 2 capsules (400 mg) by oral route in the morning and 3 capsules (600 mg) in the evening for patients weighing less than or equal to 75Kg for 24 weeks
- 2 capsules (400 mg) by oral route in the morning and 3 capsules (600 mg) in the evening (patients weighing less than or equal to 75 kg)
- 3 capsules (600 mg) by oral route 2 times per day for patients weighing more than 75 kg for 24 weeks
- 3 capsules (600 mg) by oral route 2 times per day for patients weighing more than 75 kg
- 3 tablets (600 mg) by oral route 2 times per day
- 3 capsules (600 mg) by oral route 2 times per day for patients weighing 81 kg to 105 kg
- 3 capsules (600 mg) by oral route 2 times per day for patients weighing 81 kg to 105 kg for 24 weeks
- 3 capsules (600 mg) by oral route 2 times per day for patients weighing 81 kg to 105 kg for 48 weeks
- 3 capsules (600 mg) by oral route in the morning and 4 capsules (800 mg) in the evening for patients weighing more than 105 kg
- 3 capsules (600 mg) by oral route in the morning and 4 capsules (800 mg) in the evening for patients weighing more than 105 kg for 24 weeks
- 3 capsules (600 mg) by oral route in the morning and 4 capsules (800 mg) in the evening for patients weighing more than 105 kg for 48 weeks
Chronic hepatitis C - genotype 4
- 2 capsules (400 mg) by oral route 2 times per day for patients weighing less than or equal to 65 kg
- 2 capsules (400 mg) by oral route 2 times per day for patients weighing less than or equal to 65 kg for 24 weeks
- 2 capsules (400 mg) by oral route 2 times per day for patients weighing less than or equal to 65 kg for 48 weeks
- 2 capsules (400 mg) by oral route in the morning and 3 capsules (600 mg) in the evening for patients weighing 66 kg to 80 kg
- 2 capsules (400 mg) by oral route in the morning and 3 capsules (600 mg) in the evening for patients weighing 66 kg to 80 kg for 24 weeks
- 2 capsules (400 mg) by oral route in the morning and 3 capsules (600 mg) in the evening for patients weighing 66 kg to 80 kg for 48 weeks
- 2 tablets (400 mg) by oral route 2 times per day in the morning and at bedtime
- 2 capsules (400 mg) by oral route in the morning and 3 capsules (600 mg) in the evening for patients weighing less than or equal to 75Kg
- 2 capsules (400 mg) by oral route in the morning and 3 capsules (600 mg) in the evening for patients weighing less than or equal to 75Kg for 24 weeks
- 2 capsules (400 mg) by oral route in the morning and 3 capsules (600 mg) in the evening (patients weighing less than or equal to 75 kg)
- 3 capsules (600 mg) by oral route 2 times per day for patients weighing more than 75 kg for 24 weeks
- 3 capsules (600 mg) by oral route 2 times per day for patients weighing more than 75 kg
- 3 tablets (600 mg) by oral route 2 times per day
- 3 capsules (600 mg) by oral route 2 times per day for patients weighing 81 kg to 105 kg
- 3 capsules (600 mg) by oral route 2 times per day for patients weighing 81 kg to 105 kg for 24 weeks
- 3 capsules (600 mg) by oral route 2 times per day for patients weighing 81 kg to 105 kg for 48 weeks
- 3 capsules (600 mg) by oral route in the morning and 4 capsules (800 mg) in the evening for patients weighing more than 105 kg
- 3 capsules (600 mg) by oral route in the morning and 4 capsules (800 mg) in the evening for patients weighing more than 105 kg for 24 weeks
- 3 capsules (600 mg) by oral route in the morning and 4 capsules (800 mg) in the evening for patients weighing more than 105 kg for 48 weeks
Chronic hepatitis C - genotype 5
- 2 capsules (400 mg) by oral route 2 times per day for patients weighing less than or equal to 65 kg
- 2 capsules (400 mg) by oral route 2 times per day for patients weighing less than or equal to 65 kg for 24 weeks
- 2 capsules (400 mg) by oral route 2 times per day for patients weighing less than or equal to 65 kg for 48 weeks
- 2 capsules (400 mg) by oral route in the morning and 3 capsules (600 mg) in the evening for patients weighing 66 kg to 80 kg
- 2 capsules (400 mg) by oral route in the morning and 3 capsules (600 mg) in the evening for patients weighing 66 kg to 80 kg for 24 weeks
- 2 capsules (400 mg) by oral route in the morning and 3 capsules (600 mg) in the evening for patients weighing 66 kg to 80 kg for 48 weeks
- 2 tablets (400 mg) by oral route 2 times per day in the morning and at bedtime
- 2 capsules (400 mg) by oral route in the morning and 3 capsules (600 mg) in the evening for patients weighing less than or equal to 75Kg
- 2 capsules (400 mg) by oral route in the morning and 3 capsules (600 mg) in the evening for patients weighing less than or equal to 75Kg for 24 weeks
- 2 capsules (400 mg) by oral route in the morning and 3 capsules (600 mg) in the evening (patients weighing less than or equal to 75 kg)
- 3 capsules (600 mg) by oral route 2 times per day for patients weighing more than 75 kg for 24 weeks
- 3 capsules (600 mg) by oral route 2 times per day for patients weighing more than 75 kg
- 3 tablets (600 mg) by oral route 2 times per day
- 3 capsules (600 mg) by oral route 2 times per day for patients weighing 81 kg to 105 kg
- 3 capsules (600 mg) by oral route 2 times per day for patients weighing 81 kg to 105 kg for 24 weeks
- 3 capsules (600 mg) by oral route 2 times per day for patients weighing 81 kg to 105 kg for 48 weeks
- 3 capsules (600 mg) by oral route in the morning and 4 capsules (800 mg) in the evening for patients weighing more than 105 kg
- 3 capsules (600 mg) by oral route in the morning and 4 capsules (800 mg) in the evening for patients weighing more than 105 kg for 24 weeks
- 3 capsules (600 mg) by oral route in the morning and 4 capsules (800 mg) in the evening for patients weighing more than 105 kg for 48 weeks
Chronic hepatitis C - genotype 6
- 2 capsules (400 mg) by oral route 2 times per day for patients weighing less than or equal to 65 kg
- 2 capsules (400 mg) by oral route 2 times per day for patients weighing less than or equal to 65 kg for 24 weeks
- 2 capsules (400 mg) by oral route 2 times per day for patients weighing less than or equal to 65 kg for 48 weeks
- 2 capsules (400 mg) by oral route in the morning and 3 capsules (600 mg) in the evening for patients weighing 66 kg to 80 kg
- 2 capsules (400 mg) by oral route in the morning and 3 capsules (600 mg) in the evening for patients weighing 66 kg to 80 kg for 24 weeks
- 2 capsules (400 mg) by oral route in the morning and 3 capsules (600 mg) in the evening for patients weighing 66 kg to 80 kg for 48 weeks
- 2 tablets (400 mg) by oral route 2 times per day in the morning and at bedtime
- 2 capsules (400 mg) by oral route in the morning and 3 capsules (600 mg) in the evening for patients weighing less than or equal to 75Kg
- 2 capsules (400 mg) by oral route in the morning and 3 capsules (600 mg) in the evening for patients weighing less than or equal to 75Kg for 24 weeks
- 2 capsules (400 mg) by oral route in the morning and 3 capsules (600 mg) in the evening (patients weighing less than or equal to 75 kg)
- 3 capsules (600 mg) by oral route 2 times per day for patients weighing more than 75 kg for 24 weeks
- 3 capsules (600 mg) by oral route 2 times per day for patients weighing more than 75 kg
- 3 tablets (600 mg) by oral route 2 times per day
- 3 capsules (600 mg) by oral route 2 times per day for patients weighing 81 kg to 105 kg
- 3 capsules (600 mg) by oral route 2 times per day for patients weighing 81 kg to 105 kg for 24 weeks
- 3 capsules (600 mg) by oral route 2 times per day for patients weighing 81 kg to 105 kg for 48 weeks
- 3 capsules (600 mg) by oral route in the morning and 4 capsules (800 mg) in the evening for patients weighing more than 105 kg
- 3 capsules (600 mg) by oral route in the morning and 4 capsules (800 mg) in the evening for patients weighing more than 105 kg for 24 weeks
- 3 capsules (600 mg) by oral route in the morning and 4 capsules (800 mg) in the evening for patients weighing more than 105 kg for 48 weeks
- didanosine
- Videx 2 Gram Pediatric
- Videx 4 Gram Pediatric
- Videx Ec
Contraindicated
- abacavir-lamivudine-zidovudine
- clozapine
- Clozaril
- Combivir
- deferiprone
- Fazaclo
- Ferriprox
- lamivudine-zidovudine
- Retrovir
- stavudine
- Trizivir
- Versacloz
- Zerit
- zidovudine
Severe
Moderate
- Azasan
- azathioprine
- azathioprine sodium
- Imuran
- mercaptopurine
- Purinethol
- Autoimmune hepatitis
- Chronic kidney disease stage 3B (moderate) GFR 30-44
- Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min
- Chronic kidney disease stage 5 (failure) GFr<15 ml/min
- Hemolytic anemia
- Pancreatitis
- Pregnancy
- Sickle cell disease
- Thalassemia
Contraindicated
- Acute myocardial infarction
- Bone marrow depression
- Hepatic cirrhosis
- Interstitial pneumonitis
- Myocardial ischemia
- Neutropenic disorder
- Pulmonary infiltrates
- Pure red cell aplasia
- Severe anemia
- Severe coronary artery disease
Severe
Moderate
- Anemia
- Asthma
- Chronic obstructive pulmonary disease
- Periodontitis
- Sarcoidosis
RIBAVIRIN (RIBAVIRIN)
- Respiratory syncytial virus infection
- Chronic hepatitis C - genotype 1
- Chronic hepatitis C - genotype 3
- Chronic hepatitis C - genotype 4
- Chronic hepatitis C - genotype 2
- Anemia
- Chest pain
- Dyspnea
- Hemolytic anemia
- Neutropenic disorder
- Acute abdominal pain
- Arthralgias
- Chills
- Depression
- Diarrhea
- Dizziness
- Dry skin
- Dyspepsia
- Fatigue
- Fever
- General weakness
- Headache disorder
- Irritability
- Myalgias
- Nausea
- Pruritus of skin
- Vomiting
- Weight gain
More Frequent
Severe
Less Severe
- Bacterial infection
- Leukopenia
- Pharyngitis
- Alopecia
- Anorexia
- Conjunctivitis
- Dysgeusia
- Insomnia
- Mood changes
- Nervousness
- Rhinitis
- Sinusitis
- Skin rash
- Upper abdominal pain
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute myocardial infarction
- Allergic dermatitis
- Anaphylaxis
- Angioedema
- Aplastic anemia
- Apnea
- Blurred vision
- Bone marrow depression
- Bradycardia
- Bronchospastic pulmonary disease
- Bullous dermatitis
- Cardiac arrest
- Cyanosis
- Dehydration
- Diabetes mellitus
- Drug-induced psychosis
- Hallucinations
- Hearing disorder
- Hepatic failure
- Hypotension
- Hypothyroidism
- Hypoventilation
- Idiopathic thrombocytopenic purpura
- Interstitial pneumonitis
- Kidney transplant rejection
- Liver transplant rejection
- Pancreatitis
- Pneumonia
- Pneumothorax
- Pulmonary edema
- Pulmonary hypertension
- Pulmonary infiltrates
- Pure red cell aplasia
- Retinal detachment
- Sarcoidosis
- Stevens-johnson syndrome
- Suicidal ideation
- Thrombocytopenic disorder
- Toxic epidermal necrolysis
- Urticaria
Less Severe
- Concentration difficulty
- Conjunctivitis
- Menstrual disorder
- Periodontal infection
- Skin rash
- Tooth disorder
- Vertigo
Contraindicated
None
Severe Precaution
Ribavirin (Oral)
Reports of growth inhibition in combination therapy with interferon. Limited data to determine if ultimate adult height is reduced. Safety and efficacy not established age < 3 years.
Growth delay observed when used in combination with interferon. Data insufficient to determine if adult height is reduced. Possible suicidal ideation in adolescents, observe behavior.
- 1 Day – 3 Years
- Reports of growth inhibition in combination therapy with interferon. Limited data to determine if ultimate adult height is reduced. Safety and efficacy not established age < 3 years.
- Growth delay observed when used in combination with interferon. Data insufficient to determine if adult height is reduced. Possible suicidal ideation in adolescents, observe behavior.
- 3 Years – 18 Years
- Reports of growth inhibition in combination therapy with interferon. Limited data to determine if ultimate adult height is reduced. Safety and efficacy not established age < 3 years.
- Growth delay observed when used in combination with interferon. Data insufficient to determine if adult height is reduced. Possible suicidal ideation in adolescents, observe behavior.
Management or Monitoring Precaution
None
Ribavirin
- Severity Level:
1
- Additional Notes:
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Ribavirin
Insufficient data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- Caution is advised when using this medication in people who are using a certain breathing device (ventilator). Read and follow the manufacturer's directions for use and care of the ventilator. Follow all directions from the manufacturer to prevent particle buildup in the device.<br /><br />Doing so will help the device work properly and may prevent serious side effects (e.g., air pressure buildup inside the lungs). Infrequently, sudden worsening of breathing problems may occur, especially when this medication is first started. If this occurs, treatment should be stopped. If you and the doctor decide to restart ribavirin treatment, the doctor will monitor closely to decrease the risk of side effects.
| Chronic hepatitis C - genotype 1 | |
| B18.2 | Chronic viral hepatitis C |
| Chronic hepatitis C - genotype 2 | |
| B18.2 | Chronic viral hepatitis C |
| Chronic hepatitis C - genotype 3 | |
| B18.2 | Chronic viral hepatitis C |
| Chronic hepatitis C - genotype 4 | |
| B18.2 | Chronic viral hepatitis C |
| Respiratory syncytial virus infection | |
| B97.4 | Respiratory syncytial virus as the cause of diseases classified elsewhere |
| J12.1 | Respiratory syncytial virus pneumonia |
| J20.5 | Acute bronchitis due to respiratory syncytial virus |
| J21.0 | Acute bronchiolitis due to respiratory syncytial virus |
| 0-9 | A-Z |
|---|---|
| B18.2 | Chronic viral hepatitis C |
| B18.2 | Chronic viral hepatitis C |
| B18.2 | Chronic viral hepatitis C |
| B18.2 | Chronic viral hepatitis C |
| B97.4 | Respiratory syncytial virus as the cause of diseases classified elsewhere |
| J12.1 | Respiratory syncytial virus pneumonia |
| J20.5 | Acute bronchitis due to respiratory syncytial virus |
| J21.0 | Acute bronchiolitis due to respiratory syncytial virus |
Formulary Reference Tool